The post Cuts on the table, conviction still building appeared on BitcoinEthereumNews.com. At the Treasury Select Committee (TSC) hearing following the FebruaryThe post Cuts on the table, conviction still building appeared on BitcoinEthereumNews.com. At the Treasury Select Committee (TSC) hearing following the February

Cuts on the table, conviction still building

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

At the Treasury Select Committee (TSC) hearing following the February Monetary Policy Report, Bank of England (BoE) Governor Andrew Bailey struck a cautiously dovish tone, suggesting that with inflation returning to target, there should be scope for further monetary policy easing. He said he would head into upcoming meetings asking whether a cut was justified, stressing that a move at the next meeting was “a genuinely open question.” While he expects inflation to return close to target in April and broadly sees room for cuts over the course of this year, he was careful not to pre-commit.

On the latest data, Bailey noted that headline inflation had come in broadly as expected. Goods price inflation was softer than anticipated, possibly reflecting developments in China, but services inflation had not eased as much as the Bank had hoped, a reminder that domestic price pressures remain sticky.

Chief Economist Huw Pill sounded more guarded. He acknowledged that in the past, the Bank may have placed too much weight on inflation being at the target at a point in time rather than focusing on future risks. In his view, the job of bearing down on inflationary pressures is not yet complete, implying that caution is still warranted even as the discussion shifts towards potential easing.

Taken together, the message was that cuts are clearly on the table for 2026, but not on autopilot. The direction of travel may be towards gradual easing, yet the pace will depend heavily on how services inflation and broader domestic pressures evolve in the months ahead.

Market reaction

The British Pound (GBP) now manages to gather fresh steam, prompting GBP/USD to advance to daily highs north of 1.3500 as investors continue to assess comments from BoE rate setters, while the US Dollar (USD) is also giving up some of its earlier gains.

Pound Sterling Price Today

The table below shows the percentage change of British Pound (GBP) against listed major currencies today. British Pound was the strongest against the Japanese Yen.

USD EUR GBP JPY CAD AUD NZD CHF
USD 0.08% -0.19% 0.75% 0.08% 0.00% -0.13% -0.03%
EUR -0.08% -0.26% 0.68% 0.00% -0.09% -0.21% -0.11%
GBP 0.19% 0.26% 0.95% 0.26% 0.19% 0.05% 0.15%
JPY -0.75% -0.68% -0.95% -0.67% -0.74% -0.88% -0.78%
CAD -0.08% -0.01% -0.26% 0.67% -0.08% -0.21% -0.09%
AUD -0.00% 0.09% -0.19% 0.74% 0.08% -0.14% -0.03%
NZD 0.13% 0.21% -0.05% 0.88% 0.21% 0.14% 0.10%
CHF 0.03% 0.11% -0.15% 0.78% 0.09% 0.03% -0.10%

The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the British Pound from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent GBP (base)/USD (quote).

Source: https://www.fxstreet.com/news/bank-of-england-cuts-on-the-table-conviction-still-building-202602241538

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0003689
$0.0003689$0.0003689
+2.44%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09